26 results about "Isoflavonoid" patented technology

The invention discloses a health-care food for delaying ovarian aging, which belongs to the technical field of health-care foods and comprises a composition for improving the levels of anti-mullerian test tube hormone and superoxide dismutase and functional auxiliary materials, the composition for improving the anti-muller test tube hormone and superoxide dismutase level is prepared from the following components in parts by weight: 2 to 5 parts of pyrroloquinoline quinone PQQ, 30 to 80 parts of cranberry powder and 40 to 100 parts of an isoflavone extract, and the content of the pyrroloquinoline quinone PQQ is 2 to 5 parts, the content of the cranberry powder is 30 to 80 parts, and the content of the isoflavone extract is 40 to 100 parts. The pyrroloquinoline quinone PQQ, the cranberry powder and the isoflavone extract in a specific formula have the effect of synergistically improving the levels of anti-muller test tube hormone and superoxide dismutase, and the health food prepared from the pyrroloquinoline quinone PQQ, the cranberry powder and the isoflavone extract can improve sleep, improve urinary tract infection of middle-aged women, delay ovarian aging and the like.

The invention discloses an application of polygonatum cyrtonema cyclase PcAS1 in promoting synthesis of hematoxylin A. The cyclase PcAS1 is derived from polygonatum cyrtonema, a high isoflavone compound hematoxylin A is synthesized in a plant body, and according to the application, a recombinant plant expression vector for expressing a PcAS1 gene is constructed and transformed into the plant to realize synthesis of the hematoxylin A. Based on multiple omics data such as whole genome, re-sequencing and transcriptome of polygonatum cyrtonema, key cyclase PcAS1 closely related to homoisoflavone biosynthesis is systematically mined. Through a tobacco transient expression system and a polygonatum cyrtonema hairy root transformation system, it is proved for the first time that cyclase PcAS1 can significantly promote synthesis of high isoflavone hematoxylon A, and biosynthesis of hematoxylon A is achieved in polygonatum cyrtonema for the first time.

The application relates to application of C-methylated high isoflavone compounds in preparation of antitumor drugs and belongs to the technical field of drug application. In order to solve the problem that the existing antitumor activity is not much reported, the application of C-methylated high isoflavone compounds in preparation of antitumor drugs is provided, the C-methylated high isoflavone compounds are selected from compounds shown in the following formula 1 or formula 2: the C-methylated high isoflavone compounds or pharmaceutically acceptable salts thereof are used as active ingredients for preparation of antitumor drugs for preventing and / or treating adrenal pheochromocytoma (PC-12) and / or human brain astrocytoma (U-87MG). The C-methylated high isoflavone compounds have the advantages of high activity and high inhibition capacity, can be extracted from polygonatum sibiricum and have good drug safety.

The invention discloses a glycosyl transferase combined mutant and application thereof, and aims to solve the problems that the existing wild PlUGT43 and F196Y single-point mutants thereof have narrow substrate spectrums and cannot efficiently catalyze a plurality of isoflavone derivatives with large structural differences to perform C-glycosylation reaction. The glycosyl transferase combination mutant provided by the invention is a protein which simultaneously contains five mutated sites, namely T81S, N186S, L187A, F196Y and S310P, on the basis of a wild PlUGT43 amino acid sequence as shown in SEQ ID NO.3. The glycosyl transferase combination mutant provided by the invention is a protein which is obtained by mutating five sites, namely T81S, N186S, L187A, F196Y and S310P. Compared with a wild type and an F196Y single-site mutant, the combined mutant has the advantages that the catalytic activity on classical substrates such as daidzein is improved, and efficient C-glycosylation on various substrates such as soybean dihydroaglycone, equol and resveratrol which are difficult to catalyze or extremely low in catalytic efficiency is also realized; the application potential of the glycosyl transferase in the aspect of synthesis of diversified natural products is improved.

The application relates to the technical field of fluorescence detection, in particular to a method for detecting the composition of a lithium metal negative electrode, wherein the lithium metal negative electrode is a lithium metal negative electrode after charge-discharge cycle in a lithium battery, and the method comprises the following steps: adopting an isoflavone compound as a fluorescent probe to detect the composition on the surface of the lithium metal negative electrode. Adopting the isoflavone compound as the probe can realize visual observation and quantitative detection of deposited lithium, lithium dendrites, by-products, dead lithium and a solid electrolyte interface film on the surface of the lithium metal negative electrode.

The application discloses a stem cell exosome-containing composition and application of the stem cell exosome-containing composition in preparation of a medicine with a liver damage treatment effect, and the stem cell exosome-containing composition comprises, by weight, 0.1-0.5 parts of umbilical cord mesenchymal stem cell exosome, 3-6 parts of pueraria extract, 0.2-1 part of honey, 0.06-0.32 parts of compound vitamin, 0.3-0.7 parts of olive oil, 0.08-0.2 parts of starch, 0.03-0.15 parts of glutamic acid, 0.03-0.15 parts of cysteine, 0.03-0.15 parts of glycine, 0.05-0.35 parts of glucuronolactone, 0.05-0.18 parts of sodium carboxymethyl cellulose and 22-37 parts of deionized water. The stem cell exosome can adjust cell apoptosis, growth, multiplication and differentiation pathways through the transcriptome and proteome of a receptor cell, thereby delaying the occurrence and development of liver diseases; the pueraria extract is rich in various flavones and isoflavones, can promote liver cell regeneration, and provides required nutrients for the liver in cooperation with other components, and effectively treats liver damage.

Disclosed herein are pharmaceutical formulations of isoflavonoid and methods of use.

The application discloses a method for catalyzing sodium borohydride to produce hydrogen at low temperature, which is characterized by using natural flavonoids (including flavone, flavonol, isoflavone and the like) as a catalyst, using methanol or a mixture of methanol and water as a reaction solvent, using NaBH4 as a raw material for hydrogen production, and performing alcoholysis of NaBH4 to produce hydrogen. The catalyst used in the application is abundant in source and low in price, can catalyze sodium borohydride to produce hydrogen through alcoholysis at a wide reaction temperature range, has stable catalytic performance, high hydrogen production rate, good catalytic durability and reusability, and has important significance for the application and popularization of sodium borohydride in the field of hydrogen production.

This invention relates to the field of biomedical technology, and more particularly to the application of an isoflavone compound, specifically Corylifol A, in the preparation of drugs for the prevention and / or treatment of inflammatory diseases. When used to prepare drugs for the prevention and / or treatment of inflammatory diseases, this isoflavone compound can directly bind to the IκBα protein and specifically inhibit its phosphorylation, thereby blocking the phosphorylation and nuclear translocation of the NF-κB p65 subunit, ultimately inhibiting the overactivation of the NF-κB signaling pathway. Furthermore, the isoflavone compound can significantly reduce the mortality rate of lipopolysaccharide-induced septicemia in mice, inhibit the levels of inflammatory factors in serum and lung tissue, and effectively alleviate LPS-induced acute lung injury in mice. Simultaneously, when the isoflavone compound is controlled within an effective concentration range, it exhibits no significant cytotoxicity to mouse peritoneal macrophages and can significantly inhibit the production and release of lipopolysaccharide-induced inflammatory factors IL-1β, TNF-α, and IL-6.

This invention discloses the application of isoflavone compounds in the preparation of antiviral drugs against COVID-19, relating to the field of pharmaceutical formulation technology. The isoflavone compounds are multi-target, dual-function antiviral components, meaning they can target the coronavirus replication target (SARS-CoV-2M)... pro These isoflavones (and / or RdRp) exert direct antiviral effects and can also target p17 inflammatory factors to exert anti-inflammatory effects, thus possessing dual antiviral and anti-inflammatory functions. Given the complex pathophysiology of COVID-19, its treatment should include antiviral infection and regulation of the body's immune-inflammatory system imbalance. Therefore, the aforementioned isoflavone compounds with dual functions are promising candidates for anti-COVID-19 drugs.

The invention discloses a preparation method and application of soybean-sourced nano phytoestrogen nano vesicles, belongs to the technical field of biological nano materials, solves the technical problems of poor bone targeting ability and low bioavailability of supplemented exogenous estrogens, and comprises the following steps: S1, weighing, cleaning and soaking; s2, crushing and filtering; s3, performing differential centrifugation; s4, performing extrusion to obtain nano phytoestrogen nano vesicles (SVs) from soybeans, and storing the nano phytoestrogen nano vesicles (SVs) at-80 DEG C for later use; the prepared SVs are applied to preparation of medicines for treating postmenopausal osteoporosis diseases. The soybean-sourced phytoestrogen nano-vesicle prepared by combining a differential centrifugation method with an extrusion method is wide in raw material source and simple in extraction process, is used as a plant estrogen, is rich in various bioactive components such as proteins, lipids and isoflavonoids, reverses the state of bone resorption and bone formation imbalance under the estrogen deficiency state, and has a good application prospect. And a new solution is provided for the treatment of postmenopausal osteoporosis.

The invention relates to the technical field of medicinal chemistry and pharmacotherapeutics, and mainly relates to a carborane-containing isoflavone derivative as well as a preparation method and application thereof. The carborane-containing isoflavone derivative provided by the invention is a compound as shown in a formula (I) or pharmaceutically acceptable salt thereof, and also provides a preparation method thereof, the compound shows antitumor activity in related cancer cell lines, overcomes the defect that the active action site and mechanism of the isoflavone compound are not clear, and has a good application prospect. The BNCT nano-material has good targeting property, can realize double functions of BNCT precise positioning treatment and tumor growth and migration inhibition, and has very high clinical application value.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

The invention belongs to the field of new application of medicines, and particularly relates to application of 7, 3 ', 4'-Trihydroxyisoflavone in preparation of medicines for treating obesity and related metabolic diseases of the obesity, in particular to application of 7, 3 ', 4'-Trihydroxyisoflavone in preparation of medicines for treating the obesity and the related metabolic diseases of the obesity. According to the present invention, 7, 3 ', 4'-Trihydroxyisoflavone is the natural isoflavone compound, and the molecular docking simulation results show that the compound can effectively bind to the potential active site of the GPCPD1 protein; experiments show that the compound can significantly reduce the liver weight and body weight of fat NAFLD model mice induced by high fat diet, reduce intrahepatic lipid droplet deposition and fat vacuolation degeneration, and improve liver function indexes; meanwhile, insulin resistance and abnormal blood glucose metabolism can be relieved. Therefore, the compound can be used for preparing medicines for preventing, relieving or treating obesity and related metabolic disorders, and has important clinical application value.

The invention discloses application of a cytisine-N-isoflavone derivative in preparation of a medicine for resisting non-small cell lung cancer, and belongs to the technical field of biological medicine. The derivative is a compound CNI3, and the medicine takes the compound CNI3 or a pharmaceutically acceptable solvate thereof as an active ingredient; the dosage form can be selected from tablets, capsules, granules, dripping pills, suspensions, syrups, enteric preparations, gels, suppositories, ointments, emulsions and injections, and the administration route can be selected from oral administration, injection administration, respiratory tract inhalation administration, local administration, sublingual administration and rectal administration. Experiments in combination with in-vivo cell level and in-vitro animal level prove that the compound CNI3 promotes apoptosis of non-small cell lung cancer, exerts activity of resisting non-small cell lung cancer, has no obvious toxic or side effect on normal tissue cells, is good in safety, and has a good clinical application prospect when being used for preparing the medicine for resisting non-small cell lung cancer.

This invention relates to the field of biotechnology, specifically to the construction and application of a Benzodiacetic tobacco chassis for synthesizing isoflavones. This invention reconstructs the upstream pathway for isoflavone synthesis in Benzodiacetic tobacco, further identifies and screens key rate-limiting enzymes for isoflavone synthesis in Benzodiacetic tobacco, and utilizes 2A peptides to co-express multiple key genes, further introducing flavonoid synthesis transcription factors to construct a Benzodiacetic tobacco chassis for synthesizing isoflavones. This Benzodiacetic tobacco chassis can efficiently synthesize daidzein and genistein. Furthermore, based on the constructed high-yield Benzodiacetic tobacco platform for daidzein and genistein, various isoflavones can be further synthesized, such as daidzein, genistein, puerarin, gentiopicrin, chickpea extract A, and stigmosiderin, paving the way for the industrialization of plant biosynthesis of various bioactive isoflavones and thus possessing broad application prospects.

This invention belongs to the field of biomedical technology, specifically relating to an isoflavone compound, its preparation method, and its application. This compound is derived from *Rotenoporosis capillaris* (a type of vine). Derris eriocarpa The stem of *Derris fusiforme* was analyzed using 1D and 2D nuclear magnetic resonance (NMR) spectra (1H NMR, 1C NMR, and high-resolution mass spectrometry), and its structural formula is shown below: Chemical name: 5-hydroxy-6-(2"-hydroxy-3"-methylbut-3"-enyl)-3-(4'-hydroxyphenyl)-7-methoxyisoflavone. Screening using the Sci-finder database revealed that this compound is a novel isoflavone, isolated for the first time from *Derris fusiforme*. Lipid-lowering activity experiments showed that at the same drug concentration (25 μg / mL) as the positive control, it significantly reduced intracellular total cholesterol and triglyceride levels. p <0.001). Therefore, this novel isoflavone compound can be used to prepare drugs, health products, functional foods, or special medical foods for the prevention or treatment of hypertriglyceridemia, hyperlipidemia, obesity, or metabolic syndrome.

This invention discloses a highly efficient method for the enrichment and separation of isoflavones from kudzu root, belonging to the field of traditional Chinese medicine extraction and separation technology. The method includes: adsorbing and enriching kudzu root juice using HP-20 macroporous adsorption resin, optimizing the sample loading and elution conditions, and eluting with 50% ethanol to obtain a crude isoflavone extract; then separating the crude extract using high-speed countercurrent chromatography, employing a solvent system of ethyl acetate-n-butanol-water with a volume ratio of 2:1:3 to achieve efficient and simultaneous separation of four isoflavone components: puerarin, 3′-methoxypuerarin, puerarin apigenin, and daidzein. This invention features a simple process, low solvent consumption, and high separation efficiency, simultaneously obtaining multiple high-purity isoflavone monomers, making it suitable for large-scale production.

This invention discloses the application of a natural isoflavone compound in the preparation of drugs for the prevention or treatment of depression. The natural isoflavone compound is hematoxylin A, a derivative of hematoxylin A, or a pharmaceutically acceptable salt of hematoxylin A. Hematoxylin A can effectively reduce oxidative damage to HT22 neurons in the hippocampus induced by glutamate and corticosterone, and can significantly improve the behavioral performance of mice in a chronic restraint stress depression model, exhibiting clear antidepressant activity. Hematoxylin A has a well-defined structure and good safety profile, showing promising application prospects in the development of antidepressant drugs.

The application relates to a water extract of Zhizi Chi Tang, granules and application and preparation method thereof. Zhizi Chi Tang dry extract powder is mixed with a diluent to obtain a base material; a wetting agent is added into the base material to obtain soft material; the soft material is sieved through a first sieve screen to obtain wet granules; the wet granules are dried to obtain dry material; and the dry material is whole-granulated through a second sieve screen to obtain dry granules. The water extract of Zhizi Chi Tang contains at least iridoid, isoflavone, organic acid, crocin and other substances, and has remarkable efficacy on the treatment of depression. The application reforms the dosage form of Zhizi Chi Tang by means of modern scientific research technology and method, adopts wet granulation as a granulation technology, and selects and optimizes the types of auxiliary materials and the proportion of medicine and auxiliary materials by taking the granulation of soft material, granule hardness, granule appearance, and granule yield as indexes, and the drying temperature of the granules is investigated to optimize the better forming process of the Zhizi Chi Tang granules.

The present application belongs to the technical field of traditional Chinese medicine extraction, and particularly relates to a Polygonatum involucratum extract, a preparation method and application thereof. The present application takes dry Polygonatum involucratum powder as a raw material, removes the sugar-containing part through ethanol solution extraction and gradient elution of a polystyrene macroporous resin column, achieves the purpose of enriching small molecule substances such as flavonoids, saponins and amides, and obtains a first extract which has a good recovery effect on the decrease in liver cell activity caused by lysozyme-induced amyloidosis and the decrease in liver cell activity caused by alcohol. Then, the first extract is subjected to normal phase silica gel column chromatography elution and layering, and a second extract containing high isoflavone compounds has a significant recovery effect on the decrease in liver cell activity caused by lysozyme and the decrease in liver cell activity caused by alcohol, proving that the Polygonatum involucratum extract can be applied to the preparation of drugs for reversing liver amyloidosis and alcoholic liver injury, and has important clinical application value.

The application provides a silicon-based homoisoflavonoid activated powder and a preparation method and application thereof, and belongs to the auxiliary technical field of medical detection materials. The application takes medicinal grade fumed silica (fumed silica powder) as an inorganic core, takes natural homoisoflavonoid active molecule sappanone A as an organic functional shell, and realizes uniform modification and firm anchoring of the natural active molecule on the surface of the inorganic carrier through stable covalent bonding. In the activated powder, the sappanone A as the shell is derived from a natural medicinal plant, rich in a single-double bond alternating flexible conjugated system capable of free internal rotation in the chemical structure, and has intrinsic color and intramolecular rotation regulation characteristics, and can accurately realize the visual conversion from micro-area stress change to optical signal in various medicinal diagnosis and treatment aid systems such as a gastroscope bubble driving agent, a medicinal catheter lubricating oil agent and the like, and has a congenital functional advantage at a structural level.

The invention discloses a low caffeine nerve stimulation tea wine based on bung aged wine and a preparation method thereof, the low caffeine nerve stimulation tea wine is mainly prepared by blending cherry bung aged tea wine and litchi bung aged tea wine with different baking degrees, the mass ratio of pinocembrin to syringic acid to apigenin in the wine body is (1.4-3.5): 1: (1-3), the mass ratio of chrysin to vanillic acid is 1: (0.06-0.35), and the mass ratio of the pinocembrin to the syringic acid to the apigenin is (1.4-3.5): 1: (1-3). The mass ratio of the quercetin to the dihydroquercetin to the isofraxidin is (1.5-4): 1: (0.5-2), and the total content of the pinocembrin, the syringic acid, the apigenin, the chrysin, the vanillic acid, the quercetin, the dihydroquercetin and the isofraxidin in the wine is 50-400mg / 100mL. By combining and matching the functional components in the wood and the proportion of the functional components, the antagonistic effect on caffeine nerve stimulation in the tea wine is achieved.

The invention discloses application of an isoflavone compound in preparation of a new coronavirus resisting medicine, and relates to the technical field of medicine preparations. The isoflavone compound is an antiviral component with multiple target points and double functions, not only can achieve a direct antiviral effect by targeting a coronavirus replication target (SARS-CoV-2 Mpro and / or RdRp), but also can achieve an anti-inflammatory effect by targeting a p17 inflammatory factor, and has double functions of antiviral and anti-inflammatory. In view of complex pathophysiology of the COVID-19, the treatment method of the COVID-19 comprises the steps of resisting virus infection and regulating immune-inflammation system imbalance of an organism, so that the isoflavone compound with dual functions is a promising anti-COVID-19 candidate drug.

The invention belongs to the technical field of genetic engineering and enzymology, and particularly relates to isopentenyl transferase and application thereof to preparation of isopentenyl isoflavone. The isopentenyl transferase FoPT2 with the amino acid sequence shown as SEQ ID NO.2 is verified for the first time to show catalytic activity on 6 isoflavone compounds (genistein, dihydrogenistein, biochanin A, calycosin, genistin and 3 ', 4', 7-trihydroxy isoflavone), 21 isopentenyl products are generated in total, the structures of 10 products are analyzed, and 3 products are synthesized for the first time. The isopentenylation modification comprises 13 kinds of mono-isopentenylation (C- / O-connection) and 8 kinds of diisopentenylation (C-O connection / C-C connection), modification sites comprise C-6, 7-O, C-8, 4 '-O and the like, and wide regioselectivity is shown. By optimizing reaction conditions, the catalytic efficiency of FoPT2 is improved, the preparation of isopentenyl isoflavone with various structures is facilitated, and a new possibility is provided for isopentenyl isoflavone products.

This invention relates to a novel isoflavone compound represented by formula (I), a method for preparing this compound, and its use in the preparation of neuroprotective small molecule drugs. The general chemical formula of this compound is shown in formula (I). The compound in formula (I) is prepared by reacting a polyphenolic compound with a substituted phenylacetonitrile, or by reacting a polyphenolic compound with a substituted phenylacetic acid. A series of neuroprotective activity experiments have demonstrated that the compound described in this invention possesses excellent neuroprotective activity, and the compound with the best activity also exhibits acetylcholinesterase inhibitory activity, making it suitable as a lead molecule for the development of neuroprotective and neurodegenerative disease drugs. The preparation process of this invention is simple, the raw materials are inexpensive and readily available, and the product has high purity. (I).